1. Home
  2. KVUE

as 06-28-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Consumer Discretionary

Specialty Chemicals

Nasdaq

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Founded: N/A Country:
United States
United States
Employees: N/A City: SKILLMAN
Market Cap: 36.0B IPO Year: 2023
Target Price: $22.91 AVG Volume (30 days): 24.0M
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield: 4.40% Dividend Payout Frequency: Quarterly
EPS: 0.78 EPS Growth: -33.33
52 Week Low/High: $17.75 - $26.66 Next Earning Date: 07-18-2024
Revenue: $15,486,000,000 Revenue Growth: 1.80%
Revenue Growth (this year): 3.5% Revenue Growth (next year): 3.42%

KVUE Daily Stock ML Predictions

Share on Social Networks: